Apotex Inc., Canada’s leading pharmaceutical manufacturer of generic medicines, announced today the launch of APO-ApixabanTM tablets, Canada’s first generic alternative to Eliquis®.
Apotex Inc., Canada’s driving drug maker of conventional medications, declared today the send off of APO-ApixabanTM tablets, Canada’s most memorable nonexclusive option in contrast to Eliquis®.
Apotex’s apixaban is an oral anticoagulant showed for the avoidance and treatment of hurtful blood clumps. Accessible in 2.5 mg and 5mg tablets, this item comes in different bundle sizes including 60, 180, and 500 BTL.
Accessing a conventional choice of a significant medicine like Eliquis® gives patients more reasonable open doors for the treatment of blood clusters.
Anticoagulants, otherwise called blood thinners, are managed to patients who are at a high gamble of getting blood clusters, to diminish their possibilities creating difficult circumstances, for example, strokes and coronary failures. APO-ApixabanTM adds to our anticoagulant portfolio, which as of now incorporates APO-Dabigatran.
ELIQUIS (Apixaban) has been on the market for a number of years, and available internationally.
Eliquis is registered trademark owned by Bristol-Myers Squibb Holdings who has international locations worldwide.
ELIQUIS (Apixaban) is a medication that may be prescribed for one of the following reasons:
Treat deep vein thrombosis (DVT) or pulmonary embolism (PE) and to reduce the risk of it happening again
Provide prophylaxis for DVT and PE in certain high-risk patients, like those undergoing knee or hip replacement surgery
Reduce the risk of stroke in patients with nonvalvular atrial fibrillation
If a clot forms in the veins, it can break off and lead to harmful and sometimes deadly events like a cardiovascular accident (stroke), myocardial infarction (heart attack), or PE (clot in the lungs). Certain people are at high risk of clot formation, including those who have had a clot before and those with atrial fibrillation.
Atrial fibrillation is an irregular heart rhythm where one of the chambers of the heart “quivers” instead of efficiently pumping blood. This causes blood to stay in one spot and increases the risk of a clot.
ELIQUIS works by targeting a protein in the clotting cascade, called factor Xa (Ten A). Shutting off this protein slows down clot formation, preventing their formation.
The active ingredient of ELIQUIS is apixaban.
ELIQUIS cannot be used by those with artificial heart valves.
Patients with triple phospholipid syndrome (a genetic clotting disorder) should not use ELIQUIS.
If you experience bleeding or bruising that does not stop while taking ELIQUIS, call your doctor.
Since ELIQUIS works by slowing the clotting cascade, the main side effects are related to bleeding. Examples of major bleeding events include:
Blood in the urine or stool
Example of minor side effects related to bleeding include:
Cuts that take longer to heal